Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
INGELHEIM, Germany & NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome and Boehringer Ingelheim Partners enter into co-development and license agreement for retinal disease therapies